Lv6
2250 积分 2022-10-25 加入
OP0282 POVETACICEPT (ALPN-303; TACI vTD-Fc), AN ENHANCED, POTENT DUAL INHIBITOR OF BAFF AND APRIL, DEMONSTRATES GREATER TISSUE DISTRIBUTION VERSUS WILD-TYPE TACI-Fc IN ADULT MICE AND IMPROVED EFFICACY VERSUS WILD-TYPE TACI-Fc OR ANTI-CD20 IN THE IFNα-ACCELERATED NZB/W MOUSE MODEL OF SLE
1个月前
已关闭
OP0039 ALPN-303, AN ENHANCED, POTENT DUAL BAFF/APRIL ANTAGONIST ENGINEERED BY DIRECTED EVOLUTION FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND OTHER B CELL-RELATED AUTOIMMUNE DISEASES
1个月前
已完结
Inhibition of long-lived plasma cells, a critical role for Telitacicept treatment to systemic lupus erythematosus
3个月前
已完结
BCMA biology and therapeutic targeting in multiple myeloma: From ligand signaling to antigen escape
3个月前
已完结
Structures of APRIL-Receptor Complexes
3个月前
已完结
Selectivity of BAFF/BLyS and APRIL for Binding to the TNF Family Receptors BAFFR/BR3 and BCMA
3个月前
已完结
Single Site N-Glycosylation of B Cell Maturation Antigen (BCMA) Inhibits γ-Secretase-Mediated Shedding and Improves Surface Retention and Cell Survival
6个月前
已完结
The Beautiful Structures of BAFF, APRIL, and Their Receptors
6个月前
已完结
BAFF, APRIL and their receptors: Structure, function and signaling
6个月前
已完结
Study on the Mechanism of Selective Interaction of BR3 and BCMA with BAFF and APRIL
6个月前
已完结
皖公网安备34019202002308
